According to the National Cancer Registry Ireland (NCRI), uterine cancer accounts for more than 90 per cent of endometrial carcinoma cases, registering an average annual incidence of 540 to 570 new cases and a five-year survival rate of approximately 78 per cent. Global data show that endometrial carcinoma incidence has surged by over 130 per cent over the past three decades, driven largely by population ageing, obesity—which is linked to 60 per cent of these cancers—and type 2 diabetes.
Molecular Classification Transforms Endometrial Cancer Treatment
Endometrial cancer management has shifted from traditional histological classification to detailed molecular stratification based on recommendations from the ESGO–ESTRO–ESP guidelines, according to clinical data. Tumours are now categorized into four primary groups: POLE-mutated (POLEmut), making up 5 to 10 per cent of cases; mismatch repair-deficient (MMRd), accounting for 25 to 30 per cent; no specific molecular profile (NSMP) at 40 to 50 per cent; and p53-abnormal (p53abn) representing 15 to 20 per cent of cases. A fifth subgroup capturing aggressive NSMP high-grade or oestrogen receptor-negative tumours was added in recent updates.
Multicentre cohorts and trials like PORTEC III confirm that these molecular subtypes hold independent prognostic value across all FIGO stages. POLEmut tumours carry an excellent prognosis, allowing clinicians to safely de-escalate adjuvant therapy and spare patients from the toxicity of radiotherapy and chemotherapy. Conversely, p53abn tumours carry poorer outcomes, prompting medical teams to escalate care to combined chemoradiation. Pathology services in Ireland rely on standard MMR and p53 immunohistochemistry, though challenges remain in securing widespread access to POLE sequencing.
Immunotherapy Combinations Emerge as a New Standard for Advanced Disease
Advanced or recurrent endometrial cancer treatment has been significantly altered by the introduction of immune checkpoint inhibitors. All endometrial cancers undergo routine testing for mismatch repair status to classify tumours as either proficient (MMRp) or deficient (MMRd). The phase III RUBY trial demonstrated that adding dostarlimab to carboplatin and paclitaxel resulted in a 68 per cent reduction in the risk of death for the MMRd population compared with chemotherapy alone, according to published trial data.
Similarly, the phase III NRG-GY018 trial evaluated pembrolizumab combined with paclitaxel and carboplatin. At 12 months, 74 per cent of patients with MMRd tumours treated with pembrolizumab achieved progression-free survival, compared to 38 per cent on chemotherapy alone, while MMRp groups saw a 50 per cent versus 30 per cent split. While these immunotherapy regimens have secured regulatory approvals, reimbursement in Ireland remains restricted primarily to clinical trial access, according to clinical analyses.
GLP-1 Receptor Agonists and Metabolic Adjuncts in Endometrial Care
Researchers are exploring whether GLP-1 receptor agonists can modify endometrial cancer risk or support conservative management, given the strong clinical link between obesity, insulin resistance, and endometrial carcinogenesis. A cohort study utilizing the TriNetX database involving over 444,000 women with benign uterine disease or endometrial hyperplasia found that adding a GLP-1RA to progestin therapy reduced endometrial cancer risk by 66 per cent compared with progestin alone, according to findings published in JAMA Network Open.
Preclinical work published in Clinical Cancer Research indicates that GLP-1 receptor agonists may also restore progesterone receptor expression to help overcome progestin resistance. While these findings point toward a potential therapeutic role in fertility-sparing or medically inoperable patients, the data remain observational, and GLP-1RAs are not yet incorporated into official treatment guidelines.
Fertility-Sparing Management for Younger Patients
Incidence rates are rising among premenopausal women, increasing the diagnostic challenge and the demand for fertility-sparing pathways. For younger patients with early-stage, low-grade endometrioid endometrial cancer or atypical hyperplasia who want to preserve fertility, conservative management involves hysteroscopic tumour biopsy followed by oral progestins or a levonorgestrel-releasing intrauterine device for six months, alongside weight control encouragement.
Clinical studies show response rates ranging from 75 to 80 per cent under these conservative protocols. Patient monitoring requires strict adherence, including response confirmation via two endometrial biopsies spaced at least three months apart. A definitive hysterectomy remains the recommended fallback for non-responders or patients who experience recurrence.
Pro Tip for Clinical Practice
Molecular testing at initial diagnosis is no longer optional. Clinicians must prioritize establishing MMR status to guide first-line systemic therapy choices, while ongoing health service developments aim to widen national access to POLE sequencing for all affected women.
Frequently Asked Questions
What are the primary symptoms of endometrial carcinoma that patients should monitor?
Postmenopausal bleeding is the primary sign that requires prompt clinical investigation, alongside unusual bleeding patterns in premenopausal women.
How does molecular classification impact treatment decisions?
Molecular stratification divides tumours into distinct groups—such as POLE-mutated or p53-abnormal—which helps oncologists determine whether to de-escalate adjuvant therapy or escalate care to combined chemoradiation.
Are GLP-1 receptor agonists officially approved for treating endometrial cancer?
No. While recent studies show a strong association between GLP-1RA use and reduced endometrial cancer risk in metabolic disease, these treatments are not yet part of standard clinical guidelines for cancer management.
What options exist for women who want to preserve their fertility?
Conservative management using hysteroscopic biopsy combined with oral progestins or a levonorgestrel intrauterine device is available for carefully selected younger patients with early-stage, low-grade disease.
Join the Conversation
Have questions about evolving endometrial cancer treatments or clinical trials in Ireland? Share your thoughts in the comments below or subscribe to our newsletter for updates in gynaecological oncology.
Keep reading